Chronobiology of Vascular Disorders: a “Seasonal” Link between Arterial and Venous Thrombotic Diseases?
Back to listReview article
Chronobiology of Vascular Disorders: a “Seasonal” Link between Arterial and Venous Thrombotic Diseases?
Roberto Manfredini 1, Fabio Manfredini 2, Anna Maria Malagoni 2, Benedetta Boari 3, Raffaella Salmi 3, Francesco Dentali 4 and Walter Ageno 4
Affiliations: 1Department of Clinical and Experimental Medicine, Section Clinica Medica, University of Ferrara, Ferrara, Italy; 2Vascular Diseases Center, University of Ferrara, Ferrara, Italy; 3Department of Internal Medicine, S Anna General Hospital of Ferrara, Ferrara, Italy and 4Department of Clinical Medicine, University of Insubria, Varese, Italy
ABSTRACT
Rhythmic patterns have been observed in most biological functions, and oscillations with a peak and trough have been demonstrated for many bodily functions, including arterial blood pressure, heart rate, vascular tone, coagulation, and fibrinolysis. Depending on cycle length, these oscillations can be circadian, ultradian, circannual, or seasonal. In recent decades, many studies have investigated the possibility of seasonal variations in several diseases, especially in the cardiovascular system and specifically in some arterial and venous diseases. Traditionally, the two vascular beds have been considered as separate entities, each characterized by its own risk factors and diseases. Recently, however, a series of findings has revealed analogs between these two entities that are also supported by chronobiological findings. The latest findings about seasonal variations in major arterial and venous diseases and possible common underlying risk factors are presented and discussed here.
Keywords: Chronobiology, seasons, acute myocardial infarction, stroke, aortic diseases, venous thromboembolism, pulmonary embolism
Correspondence: Roberto Manfredini, Department of Clinical and Experimental Medicine, Section Clinica Medica, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy. Tel: (39)‐0532‐236817; Fax: (39)‐0532‐236816; e‐mail: mfr@unife.it
Other Articles
- Prophylaxis with Once, Twice or Three-Times Weekly Dosing of rFVIII-FS prevents Joint Bleeds in a Previously Treated Pediatric Population with Moderate/Severe Hemophilia A
- Current Practice in Clinical Thrombosis and Hemostasis
- Review of the Literature of FEIBA Administration in Patients with Hemophilia B and Inhibitors
- Decreased Bone Mineral Density in Adult Patients with Hemophilia: Clinical Significance, Prevalence and Risk Factors
- Safety of Recombinant Factor VIII Therapy: Focus on Inhibitor Development
